



FOR IMMEDIATE RELEASE

ASHLAND, OHIO - November 26, 2008 - Joseph F. Holson, PhD, DABFE, President of WIL Research Laboratories, LLC ("WIL Research"), today announced he will be retiring from WIL Research.



As part of WIL Research's succession plan, the Board of Directors of WIL Research Holding Company, Inc. is proud to announce it has elected **Mark D. Nemec**, BS, DABT as President and Chief Operating Officer (COO), WIL Research Laboratories, LLC, effective immediately.

Mr. Nemec has over 32 years of industrial experience in developmental and reproductive toxicology, has served in a directorial capacity at WIL Research for the last 13 years and is certified by The American Board of Toxicology. Mr. Nemec received a Bachelor of Science degree in Biomedical Sciences from Western Michigan University in 1977. He was hired by WIL Research in 1982 as Manager of Reproductive and Developmental Toxicology to establish this discipline of scientific study for the company. He became an Associate Director in 1990, and has served as the Director of Developmental and Reproductive Toxicology at WIL Research since 1995. He is affiliated with several scientific societies, including the Teratology Society, the Neurobehavioral Teratology Society, the American College of Toxicology (ACT), the Middle Atlantic Reproduction and Teratology Association (MARTA) and the Midwest Chapter of the Society of Toxicology (SOT). Mr. Nemec has authored or coauthored numerous book chapters, articles and abstracts for scientific publications.



Christopher Chengelis, PhD, DABT has been named Vice President and Chief Scientific Officer, WIL Research Laboratories, LLC. Dr. Chengelis has worked in the academic and private sectors in the discipline of toxicology since 1980 in the areas of general and biochemical toxicology, pharmacokinetics, and risk assessment. Dr. Chengelis joined WIL Research in 1990 as Associate Director of Toxicology and was promoted to Director of Toxicology in 1997. Under his leadership, the Toxicology department has grown to become the largest department in the company. His active memberships include the Society of Toxicology, the American College of Toxicology (ACT), and the American Society of Pharmacology and Experimental Therapeutics. He is a past president of the ACT and also the Midwest Regional Chapter SOT. Dr. Chengelis has published numerous abstracts, papers and book chapters in the areas of toxicology and drug metabolism and has served on the editorial board of two peer-reviewed toxicology journals.

Also assuming new roles are **Donald Stump**, PhD, DABT and **Jozef Mertens**, PhD, DABT. Dr. Stump will be assuming the position of Director, Developmental and Reproductive Toxicology. He joined WIL Research in 1994 and has been the Associate Director, Developmental and Reproductive Toxicology since 2000. Prior to joining WIL Research, Dr. Stump completed a post doctoral research fellowship at The National Institutes of Health (NIH). Dr. Stump received a PhD in biochemistry from Vanderbilt University in 1990. Dr. Stump has been critical in continuing the WIL Research tradition in offering the premier service in Developmental and Reproductive Toxicology in the contract research organization sector. Dr. Stump was recently honored by the scientific community in Japan as an invited speaker to the Japanese Teratology Society Meeting in Kagoshima to be held in June 2009. Dr. Stump has clearly forged a strong scientific presence during his tenure at WIL Research.



Dr. Jos Mertens will be assuming the position of Director, General Toxicology. He joined WIL Research in 1995 and has been the Associate Director of Toxicology since 2002. In 1984 he obtained his MS degree in Agriculture and Environmental Sciences after completion of research projects in physiology, neurotoxicology, immunotoxicology and *in vitro* toxicology. His later work at the University in Wageningen, on the development of an *in vitro* model for studying mechanisms of nephrotoxicity resulted in a PhD degree in January 1991. He came to the United States in 1991 for post-doctoral work in the area of quinone thioether-induced nephro and neurotoxicity at the University of Texas in Austin. Among his many accomplishments, Dr. Mertens has overseen the development of WIL Research's non-human primate capabilities.

About WIL Research Laboratories, LLC

WIL Research Laboratories, LLC is a contract research organization (CRO) headquartered in Ashland, Ohio that provides an interdisciplinary approach to toxicology, pharmacology, metabolism, and bioanalytical services to the pharmaceutical, biotechnology, chemical, agricultural, veterinary and food and consumer products industries.

WIL Research Laboratories, LLC develops the most effective research studies available in the market today with the expertise to conduct, interpret and report results to both domestic and international regulatory agencies. For more information, visit www.wilresearch.com

Contact:

1-800-221-9610